Jeffrey E. Gershenwald

Jeffrey E. Gershenwald is a Professor (term-tenured) at The University of Texas MD Anderson Cancer Center, specializing in surgical oncology, melanoma, and cancer immunotherapy. His research focuses on the molecular biology of melanoma lymphatic metastasis, germline cancer susceptibility variants in mucosal melanoma, and the optimization of neoadjuvant immunotherapy regimens, including anti-LAG3 and anti-PD1 combinations, for resectable disease. He has led global initiatives on sentinel node risk prediction and perioperative therapy for melanoma metastasis, with recent work published in the Journal of Clinical Oncology, The Lancet Oncology, and npj Genomic Medicine. His funded projects have examined the clinical, molecular, and immune features of sentinel lymph node metastasis, supported by awards exceeding $1.2 million.